# US 2023/0416270 A1 · Novel camptothecin derivative, composition comprising same and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0416270 A1
- Document ID: US20230416270A1
- Status: Published application
- Kind: A1
- Application number: 18/039,229
- Filed: 2021-12-09
- Published: 2023-12-28
- Earliest claimed: 2020-12-11
- Assignees: Wigen Biomedicine Technology (Shanghai) Co., Ltd.
- Applicants: Wigen Biomedicine Technology (Shanghai) Co., Ltd.
- Inventors: Yuli XIE; Gang CAO; Houxing FAN; Lihui QIAN
- Web page: https://patentgrep.com/patent/US20230416270A1

## CPC

- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- C07D 495/22: in which the condensed system contains four or more hetero rings
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 47/68037: {the drug being a camptothecin [CPT] or derivatives}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61P 35/00: Antineoplastic agents
- C07D 491/22: in which the condensed system contains four or more hetero rings
- C07K 16/32: against translation products of oncogenes
- C07B 2200/07: Optical isomers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention provides a camptothecin derivative, a composition comprising the same and use thereof. Specifically, the present invention provides a compound of formula (1) and a preparation method therefor, and use of the compound of general formula (1) and optical isomers, crystalline forms and pharmaceutically acceptable salts thereof in the preparation of a medicament for treating cancer.

## Claims

### Claim 1

A camptothecin derivative compound of general formula (1) or optical isomers, crystalline forms, pharmaceutically acceptable salts, hydrates or solvates thereof:
wherein, in general formula (1):
m is an integer of 0, 1 or 2;
X is selected from —O—, —S—, —S(O)—, —S(O2)—, and —N(R4)—;
R1 and R2 are independently selected from H, halogen, OH, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C3-6 cycloalkyl, NH2, NO2, and CN, or R1 and R2, together with the phenyl ring attached thereto, form
by cyclization;
R3 is selected from C1-6 alkyl, C2-6 alkenyl, C1-3 alkoxy-substituted C1-3 alkyl, and C1-6 haloalkyl;
R4 is selected from H, C1-6 alkyl and C1-6 haloalkyl;
R5 is selected from H, C1-6 alkyl and C3-6 cycloalkyl;
R6 and R7 are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, and C3-6 cycloalkyl; or
R6 and R7, together with the carbon atom attached thereto, form C3-6 cycloalkyl or 4-7 membered heterocycloalkyl by cyclization; or R6 and R5 are linked to form a 5-7 membered lactam ring, and R7 is selected from H, C1-6 alkyl, C1-6 haloalkyl, and C3-6 cycloalkyl;
R8 is selected from OH and NR9R10, and R9 and R10 are independently selected from H, C1-6 alkyl and C3-6 cycloalkyl; or R9 and R10, together with the N atom attached thereto, form 4-7 membered heterocycloalkyl by cyclization, and the 4-7 membered heterocycloalkyl is unsubstituted or substituted with 1-3 groups selected from the following: C1-6 alkyl, halogen, OH, CN, and NH2.

### Claim 2 (depends on 1)

The camptothecin derivative compound of formula (1) or the optical isomers, the crystalline forms, the pharmaceutically acceptable salts, the hydrates or the solvates thereof according to claim 1, wherein in the formula (1), R8 is OH.

### Claim 3 (depends on 1)

The camptothecin derivative compound of formula (1) or the optical isomers, the crystalline forms, the pharmaceutically acceptable salts, the hydrates or the solvates thereof according to claim 1, wherein in the formula (1), R1 and R2 are independently selected from H, halogen, OH, Me, Et, OMe, OEt, CF3, NH2, NO2, and CN; or R1 and R2, together with the phenyl ring attached thereto, form
by cyclization.

### Claim 4 (depends on 1)

The camptothecin derivative compound of formula (1) or the optical isomers, the crystalline forms, the pharmaceutically acceptable salts, the hydrates or the solvates thereof according to claim 1, wherein in the formula (1), R3 is selected from Me, Et,

### Claim 5 (depends on 1)

The camptothecin derivative compound of formula (1) or the optical isomers, the crystalline forms, the pharmaceutically acceptable salts, the hydrates or the solvates thereof according to claim 1, wherein in the formula (1), X is selected from —O—, —S—, —S(O)—, —S(O2)—, —N(H)—, and —N(Me)-.

### Claim 6 (depends on 1)

The camptothecin derivative compound of formula (1) or the optical isomers, the crystalline forms, the pharmaceutically acceptable salts, the hydrates or the solvates thereof according to claim 1, wherein in the formula (1), R5 is selected from H, Me, Et, and

### Claim 7 (depends on 1)

The camptothecin derivative compound of formula (1) or the optical isomers, the crystalline forms, the pharmaceutically acceptable salts, the hydrates or the solvates thereof according to claim 1, wherein in the formula (1), R6 and R7 are independently selected from H, Me, Et, CHF2, CF3, CH2CF3,

### Claim 8 (depends on 1)

The camptothecin derivative compound of formula (1) or the optical isomers, the crystalline forms, the pharmaceutically acceptable salts, the hydrates or the solvates thereof according to claim 1, wherein in the formula (1),
is selected from

### Claim 9 (depends on 2)

The camptothecin derivative compound of formula (1) or the optical isomers, the crystalline forms, the pharmaceutically acceptable salts, the hydrates or the solvates thereof according to claim 2, wherein in the formula (1), R8 is OH, and
is selected from

### Claim 10 (depends on 1)

The camptothecin derivative compound of formula (1) or the optical isomers, the crystalline forms, the pharmaceutically acceptable salts, the hydrates or the solvates thereof according to claim 1, wherein the compound has one of the following structures:

### Claim 11 (depends on 1)

The camptothecin derivative compound of formula (1) or the optical isomers, the crystalline forms, the pharmaceutically acceptable salts, the hydrates or the solvates thereof according to claim 1, wherein the compound has one of the following structures:

### Claim 12

A camptothecin derivative compound or optical isomers, crystalline forms, pharmaceutically acceptable salts, hydrates or solvates thereof, wherein the compound has one of the following structures:

### Claim 13

A camptothecin derivative compound or optical isomers, crystalline forms, pharmaceutically acceptable salts, hydrates or solvates thereof, wherein the compound has one of the following structures:

### Claim 14 (depends on 1)

Use of the camptothecin derivative compound of general formula (1) or the optical isomers, the crystalline forms, the pharmaceutically acceptable salts, the hydrates or the solvates thereof according to claim 1 as a small molecule toxin in the preparation of an antibody-drug conjugate.

### Claim 15 (depends on 1)

A pharmaceutical composition, comprising a pharmaceutically acceptable excipient or carrier, and the camptothecin derivative compound of general formula (1) or the optical isomers, the crystalline forms, the pharmaceutically acceptable salts, the hydrates or the solvates thereof according to claim 1 as an active ingredient.

### Claim 16 (depends on 1)

Use of the camptothecin derivative compound of general formula (1) or the optical isomers, the crystalline forms, the pharmaceutically acceptable salts, the hydrates or the solvates thereof according to claim 1 in the preparation of a medicament for treating cancer diseases.

### Claim 17 (depends on 1)

An antibody-drug conjugate, comprising an antibody, a small molecule toxin, and a linker, wherein the small molecule toxin is the camptothecin derivative compound of general formula (1) or the optical isomers, the crystalline forms, the pharmaceutically acceptable salts, the hydrates or the solvates thereof according to claim 1, and the linker links the antibody and the small molecule toxin via a covalent bond.

### Claim 18 (depends on 17)

The antibody-drug conjugate according to claim 17, wherein the antibody-drug conjugate has one of the following structures:
wherein Ab represents a monoclonal antibody, preferably an anti-her2 antibody, and more preferably trastuzumab; n is a number from 2 to 8, preferably from 4 to 8, and more preferably from 7 to 8.
